In 2023, the number of confirmed RR-/MDR-TB cases in the US was stable compared to previous years. The forecasted data from 2024 to 2028 shows a consistent downward trend with a decline in cases from 95 in 2024 to 86 in 2028. This represents an average decrease of around 2% year-on-year over the five-year period, indicating effective strategies in combating RR-/MDR-TB.

Future trends to watch for include:

Advancements in medical technology and drug treatments which may further reduce case numbers.
Effective public health policies and increased awareness that could sustain the declining trend.
Monitoring the emergence of any new resistant strains that could impact these forecasts.